Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A.

Nature. 1998 Dec 17;396(6712):699-703.

PMID:
9872321
2.

A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.

Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS.

J Biol Chem. 1999 May 14;274(20):13733-6.

3.

Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas.

Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M.

Cancer Lett. 2000 Nov 10;160(1):89-97.

PMID:
11098089
4.

Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.

Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE.

Biochem Pharmacol. 2003 Feb 15;65(4):657-67.

PMID:
12566095
5.

Modulation of dendritic cell differentiation and maturation by decoy receptor 3.

Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL.

J Immunol. 2002 May 15;168(10):4846-53.

6.

Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen.

Kawamoto K, Tanemura M, Nishida T, Fukuzawa M, Ito T, Matsuda H.

Transplantation. 2006 Mar 15;81(5):789-96.

PMID:
16534484
7.

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

O'Connell J, O'Sullivan GC, Collins JK, Shanahan F.

J Exp Med. 1996 Sep 1;184(3):1075-82.

8.

Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen.

Matute-Bello G, Liles WC, Frevert CW, Dhanireddy S, Ballman K, Wong V, Green RR, Song HY, Witcher DR, Jakubowski JA, Martin TR.

J Infect Dis. 2005 Feb 15;191(4):596-606. Epub 2005 Jan 5.

PMID:
15655784
9.
10.

In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.

Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, LaFleur DW, Okoye Z, Salcedo TW, Santiago G, Ullrich S, Wei P, Windle K, Wong E, Yao XT, Zhang YQ, Zheng G, Moore PA.

J Pharmacol Exp Ther. 2001 Jul;298(1):25-33.

11.

Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3B.

Kim HR, Park HJ, Park JH, Kim SJ, Kim K, Kim J.

Cancer Immunol Immunother. 2004 May;53(5):461-70. Epub 2003 Nov 28.

PMID:
14648068
12.

Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.

Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E.

J Pathol. 2003 Oct;201(2):268-77.

PMID:
14517844
13.

Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.

Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M.

J Immunol. 2003 Jun 1;170(11):5406-13.

14.
15.

Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M.

Cancer Res. 2001 Mar 15;61(6):2759-65.

16.

Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.

Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y.

Acta Neuropathol. 2005 Mar;109(3):294-8. Epub 2004 Dec 31.

PMID:
15627206
17.

Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.

Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ.

J Biol Chem. 2004 Oct 15;279(42):44211-8.

18.

A membrane-bound Fas decoy receptor expressed by human thymocytes.

Jenkins M, Keir M, McCune JM.

J Biol Chem. 2000 Mar 17;275(11):7988-93.

19.

The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.

Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y.

Gastric Cancer. 2002;5(2):61-8.

PMID:
12111580
20.

Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.

Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen-Schaub LB, Roth JA, Tanaka N.

Oncogene. 1999 Apr 1;18(13):2189-99.

Supplemental Content

Support Center